Novo Nordisk's U.S. shares plummeted late Tuesday after the company said it sees sales and profit growth declining this year, expecting a sales hit.The company published the forecast as it reported full-year 2025 sales, ahead of the quarterly report expected Wednesday morning. Novo's American depositary shares fell 11% as of 12:05 pm ET. The results were published after the closing bell in Copenhagen, where the company has its primary listing.Its forecast comes as the Danish drugmaker is fighting to regain ...

The Ozempic and Wegovy maker reports full-year sales of 309.1 billion Danish krone, beating analysts' forecasts. ...

Novo Nordisk A/S shares plunged after the company shocked investors by forecasting a steep decline in sales, evidence of an intensifying price war in obesity drugs. Sales will fall by as much as 13% this year, the company said Tuesday. Pressure from lower prices for its blockbuster weight-loss drugs, in part due to the US government’s push to cut prices, will contribute to the decline. Most Read from Bloomberg “It really paints a picture of a challenged Novo,” Lars Hytting, head of trading at ArthaScop ...

Wegovy maker Novo Nordisk expects a decline in sales this year, it said on Tuesday as it reported fourth-quarter operating profit slightly above forecasts. ...

Core Insights - Novo Nordisk (NVO) announced positive top-line data from its late-stage REIMAGINE clinical study program for CagriSema, a next-generation treatment for type II diabetes (T2D) [1] Group 1: CagriSema Efficacy - CagriSema is a fixed-dose combination of cagrilintide (2.4 mg) and Wegovy (semaglutide 2.4 mg), showing superior HbA1c reduction and weight loss at week 68 compared to semaglutide across all tested doses [2] - In the phase III REIMAGINE 2 study, CagriSema demonstrated a 1.91 percentage-point reduction in HbA1c from a baseline of 8.2%, compared to a 1.76 percentage-point reduction with semaglutide [4] - Patients receiving the higher CagriSema dose achieved a 14.2% reduction in body weight from a mean baseline of 101 kg, compared to a 10.2% reduction with semaglutide [5] Group 2: Study Details - The phase III REIMAGINE 2 study involved 2,728 adults with T2D inadequately controlled with metformin, comparing two CagriSema doses against semaglutide and placebo [3] - Approximately 40% of participants were already using an SGLT2 inhibitor, providing insights into CagriSema's performance in common treatment backgrounds [3] Group 3: Safety Profile - CagriSema's safety profile was consistent with established incretin and amylin therapies, with mostly mild gastrointestinal events that tended to diminish over time [10] - The treatment regimen estimand analysis showed a superior HbA1c reduction of 1.80 percentage points and weight loss of 12.9% for CagriSema compared to semaglutide's 1.68 percentage points and 9.2% weight loss [9] Group 4: Future Development - Novo Nordisk is evaluating CagriSema in additional phase III studies for T2D and obesity, with plans to discuss regulatory pathways following positive data from the REIMAGINE and REDEFINE studies [11][12] - A regulatory application for CagriSema to reduce excess body weight is expected to be reviewed by the FDA in 2026 [13][14]

Financial Performance - Net sales for 2025 reached DKK 309,064 million, representing a 6% increase compared to 2024, and a 10% increase at constant exchange rates (CER) [2] - Operating profit decreased by 1% in Danish kroner to DKK 127,658 million, but increased by 6% at CER [2][4] - Net profit for 2025 was DKK 102,434 million, a 1% increase from DKK 100,988 million in 2024 [2] - Diluted earnings per share rose by 2% to DKK 23.03 from DKK 22.63 in 2024 [2] Market and Product Insights - Novo Nordisk achieved a 10% sales growth at CER, reaching nearly 46 million patients with its treatments despite a challenging year [3] - Sales in US Operations increased by 3% in Danish kroner and 8% at CER, while International Operations saw a 10% increase in Danish kroner and 14% at CER [4] - Sales in Obesity and Diabetes care grew by 7% in Danish kroner to DKK 289.5 billion, driven by a 26% increase in Obesity care and a 2% increase in GLP-1 diabetes sales [4] Future Outlook - Adjusted sales growth for 2026 is expected to be between -5% to -13% at CER, influenced by lower realized prices and increased competition [4] - The global GLP-1 market is anticipated to expand, with new treatments like the Wegovy pill expected to enhance patient reach [4] - The company plans to propose a final dividend of DKK 7.95 per share for 2025, totaling DKK 11.70 for the year, and initiate a new share repurchase program of up to DKK 15 billion [4]

Bagsværd, Denmark, 3 February 2026 – Novo Nordisk today announced sales and operating profit growth at constant exchange rates (CER) for 2025 and released the 2026 full-year sales and operating profit outlook at CER. 2025 sales and operating profit growth at CERIn 2025, Novo Nordisk’s sales increased by 10% and operating profit increased by 6%, compared to previously issued guidance of 8 to 11% sales growth and 4 to 7% operating profit growth1. Sales in US Operations were positively impacted by gross-to-net ...

在试验中，接受CagriSema 2.4 mg/2.4 mg治疗的患者，与赛美特鲁肽2.4 mg相比，HbA1c下降了1.91%，而赛美特鲁肽则为1.76%。体重方 面，CagriSema组的患者体重下降了14.2%，而赛美特鲁肽组为10.2%。更令人印象深刻的是，CagriSema 2.4 mg/2.4 mg组中，43%的患者达到 了15%以上的减重，24%的患者减重超过20%。 整理 | GLP1减重宝典内容团队 诺和诺德近日发布了REIMAGINE 2期临床试验的结果，CagriSema（联用卡格林肽与赛美特鲁肽）在68周内表现出优异的减重和血糖控制效 果。该试验评估了CagriSema与单独使用赛美特鲁肽的效果，结果表明，CagriSema不仅在减重方面领先，还在降低HbA1c方面超过了赛美特鲁 肽。 该研究确认了CagriSema在糖尿病管理中的潜力，尤其是在联合使用卡格林肽和赛美特鲁肽后，取得了相较单独治疗更为优越的效果。 CagriSema的安全性良好，大多数胃肠道不良事件为轻度或中度，随着治疗的进行，这些症状逐渐缓解。 *本文仅供医疗卫生专业人士参考 诺和诺德表示，基于这些令人鼓舞的临床数据， ...

Core Viewpoint - Semaglutide, a GLP-1 receptor agonist, effectively aids in weight loss by enhancing insulin secretion, suppressing glucagon secretion, delaying gastric emptying, and increasing satiety, leading to reduced appetite and food intake [4][6]. Mechanism of Action - Semaglutide activates specific neurons in the hypothalamus, signaling a feeling of fullness before eating, which is particularly effective in treating obesity [5]. - The appetite-reducing effects of semaglutide occur through three main mechanisms: - Central action: It acts on the hypothalamus to reduce appetite and hunger [6]. - Gastrointestinal action: It slows gastric emptying, increasing feelings of fullness [6]. - Altered food preferences: Patients show a significant decrease in preference and intake of high-fat, fried, or sweet foods [6]. Clinical Efficacy - In clinical trials, patients using semaglutide for 68 weeks lost an average of 15.3 kg, compared to 2.6 kg in the placebo group, with a weight reduction rate of 14.9% versus 2.4% [4]. - The approval of semaglutide for weight management in China is expected to provide a breakthrough solution for overweight and obese patients, enhancing access to effective treatment [13]. Regulatory Approvals - In January 2024, oral semaglutide (Rybelsus) was approved in China for treating type 2 diabetes, marking the first oral GLP-1 receptor agonist approved in the country [9]. - On June 25, 2024, the NMPA approved Wegovy, a semaglutide injection for long-term weight management in China [11]. - The approval of oral semaglutide in the U.S. in December 2025 for weight management and cardiovascular risk reduction signifies a new phase in weight loss medication competition [15][16]. Clinical Trial Data - The OASIS clinical trial demonstrated that daily administration of 25 mg oral semaglutide resulted in an average weight loss of 16.6% over 64 weeks, comparable to the 2.4 mg weekly injection [17]. - Approximately one-third of participants achieved a weight loss of 20% or more, addressing previous concerns about the efficacy of oral GLP-1 treatments [17].

Core Viewpoint - ResMed, a maker of sleep-breathing devices, is launching a global doctor education program to promote the screening of patients seeking Ozempic-style weight loss drugs for sleep apnea [1] Group 1: Company Initiatives - ResMed plans to implement a global education program aimed at doctors to enhance awareness and screening for sleep apnea among patients using GLP-1 receptor agonists like Ozempic [1] - The initiative reflects ResMed's commitment to addressing the intersection of weight loss treatments and sleep health [1] Group 2: Industry Context - The rise in popularity of Ozempic and similar weight loss drugs has prompted a need for increased screening for sleep apnea, as these medications can impact respiratory health [1] - The program aims to educate healthcare providers on the importance of screening for sleep apnea in patients who are prescribed these weight loss medications [1]